Neurotech InternationalNTILF 34 Days Payable is 0.00 as of Dec. 2025. GuruFocus rates NTILF with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 706 Biotechnology companies, Neurotech International ranks worse than 141642.92% on this metric.
The historical rank and industry rank for Neurotech International's Days Payable or its related term are showing as below:
During the past 9 years, Neurotech International's highest Days Payable was 35770.00. The lowest was 113.96. And the median was 1707.83.
NTILF's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.56 * Ranked among companies with meaningful Days Payable only.
Neurotech International's Days Payable
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
Neurotech International Days Payable Related Terms
Neurotech International Days Payable Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NTILF vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Neurotech International's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurotech International Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neurotech International's Days Payable distribution charts can be found below:
* The bar in red indicates where Neurotech International's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Neurotech International's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurotech International (NTILF) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Neurotech International and its competitors. Over the past decade, Neurotech International's Days Payable has ranged from 113.96 to 35,770.00. According to the industry distribution chart, Neurotech International ranks #999999 out of 706 companies in the Biotechnology industry.
Is Neurotech International's Days Payable too high?
Neurotech International's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 113.96 to a high of 35,770.00. Based on the distribution chart, Neurotech International ranks #999999 out of 706 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Neurotech International has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Neurotech International's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neurotech International ranks #999999 out of 706 companies for Days Payable. This places Neurotech International in the lower half of its industry. The industry median Days Payable is 113.56. Historically, Neurotech International's own Days Payable has ranged from 113.96 to 35,770.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Neurotech International and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurotech International's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurotech International stock overvalued right now?
Neurotech International (NTILF) has a current Days Payable of 0.00. The current Days Payable is 0.00. Neurotech International's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Neurotech International (NTILF), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.
34GF Score
Get the complete analysis for NTILF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NTILF has been successfully added to your 
